Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ritter Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13


Posted on: 05 Mar 18

LOS ANGELES, March 05, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on establishing the first FDA-approved treatment for lactose intolerance, today announced that the Company will present at the 30th Annual ROTH Conference on March 13, 2018, at 8:00 a.m. PT in Dana Point, California.

Ritter Pharmaceuticals’ management team will also be available to participate in one-on-one meetings with investors on March 12-13. Conference participants who are interested in scheduling a meeting should Email oneononerequests@roth.com.

The conference will be held March 11-14, 2018, at the Ritz Carlton in Dana Point, California.

The Company’s presentation will be available for the public to access at www.ritterpharma.com.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product, RP‐G28, has the potential to become the first FDA‐approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 has been studied in Phase 2 trials and is now in Phase 3 clinical development. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno‐oncology, metabolic, and liver disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements refer to future plans and expectations, including statements regarding the timing of our first Phase 3 pivotal clinical trial. Management believes that these forward-looking statements are reasonable as and when made.  However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could affect the Company’s actual results are included in the Company’s SEC filings, including the Company’s most recent reports on Form 10-K and 10-Q filed with the SEC. These forward-looking statements are made only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Contact:
Jeffrey Benjamin
310-203-1000
jeffrey@ritterpharma.com

GlobeNewswire
globenewswire.com

Last updated on: 05/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.